Declarations of interest: We declare no conflicts of interest.
The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy
Article first published online: 5 JUN 2014
© 2014 Wiley Periodicals, Inc.
Journal of Surgical Oncology
Volume 110, Issue 4, pages 476–481, September 15, 2014
How to Cite
Shiota, M., Yokomizo, A., Takeuchi, A., Imada, K., Kiyoshima, K., Inokuchi, J., Tatsugami, K. and Naito, S. (2014), The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy. J. Surg. Oncol., 110: 476–481. doi: 10.1002/jso.23677
- Issue published online: 6 AUG 2014
- Article first published online: 5 JUN 2014
- Manuscript Accepted: 14 MAY 2014
- Manuscript Received: 14 FEB 2014
- Kakenhi. Grant Numbers: 24890160, 25462484
- Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT), Japan
- metabolic syndrome;
- prostate cancer;
- radical prostatectomy;
- risk factor
Background and Objective
To examine the association between the features of metabolic syndrome (MetS) (obesity, hypertension, diabetes mellitus, and dyslipidemia) and the risk of biochemical recurrence (BCR) after radical prostatectomy in patients with prostate cancer.
This study included 283 Japanese patients with localized prostate cancer who were treated with radical prostatectomy between 2008 and 2012. Their oncological outcomes and the prognostic significance of several clinicopathological factors, as well as the features of MetS, were analyzed.
Of 283 men who underwent radical prostatectomy, 49 (17.2%) subsequently developed BCR with a median postoperative follow-up of 14.8 months. Among the clinicopathological factors, prostate-specific antigen (PSA) level at diagnosis, pathological stage, pathological Gleason score, and lymph-node involvement were independent risk factors for BCR in multivariate analysis. In addition, the number of metabolic risk factors was also an independent risk factor for BCR.
The features of MetS were linked with poorer outcome after radical prostatectomy among Japanese men. Further investigations are needed to determine the effect of improving MetS on prostate cancer prognosis. J. Surg. Oncol. 2014; 110:476–481. © 2014 Wiley Periodicals, Inc.